Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer Who Are Chemotherapy-Naïve

NCT00089856 is registered in ClinicalTrials.gov with Cell Genesys as lead sponsor.

NCT NCT00089856
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00089856 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized, Open-Label Study of CG1940 and CG8711 Versus Docetaxel and Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer Who Are Chemotherapy-Naïve
Lead sponsor
Cell Genesys
Phase
Phase 3
Overall status
Terminated
Start date
July 31, 2004
Completion date
October 31, 2008
Enrollment
626 (actual)
Sites
126

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer